Titre : Chimiokines CXC

Chimiokines CXC : Questions médicales fréquentes

Termes MeSH sélectionnés :

Leg Length Inequality

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dysrégulation des chimiokines CXC ?

Des tests sanguins et des analyses de cytokines peuvent aider à évaluer les niveaux de chimiokines.
Chimiokines Cytokines
#2

Quels tests sont utilisés pour mesurer les chimiokines CXC ?

Les dosages ELISA et les tests multiplex sont couramment utilisés pour mesurer les chimiokines.
Chimiokines Tests de laboratoire
#3

Les chimiokines CXC sont-elles liées à des maladies spécifiques ?

Oui, elles sont souvent associées à des maladies inflammatoires et auto-immunes.
Maladies auto-immunes Inflammation
#4

Peut-on détecter les chimiokines CXC dans les biopsies ?

Oui, les chimiokines peuvent être détectées dans les tissus par immunohistochimie.
Biopsie Immunohistochimie
#5

Les niveaux de chimiokines CXC varient-ils selon l'âge ?

Oui, les niveaux de chimiokines peuvent varier avec l'âge et l'état de santé général.
Âge Santé

Symptômes 5

#1

Quels symptômes sont associés à une surproduction de chimiokines CXC ?

Les symptômes incluent inflammation, douleur, fatigue et troubles immunitaires.
Inflammation Douleur
#2

Les chimiokines CXC peuvent-elles causer des symptômes respiratoires ?

Oui, elles sont impliquées dans des maladies respiratoires comme l'asthme et la BPCO.
Asthme BPCO
#3

Comment les chimiokines CXC affectent-elles le système nerveux ?

Elles peuvent contribuer à des troubles neurologiques en modulant l'inflammation cérébrale.
Système nerveux Inflammation cérébrale
#4

Les chimiokines CXC sont-elles liées à des symptômes cutanés ?

Oui, elles peuvent être impliquées dans des maladies cutanées inflammatoires comme le psoriasis.
Psoriasis Maladies cutanées
#5

Peut-on observer des symptômes digestifs liés aux chimiokines CXC ?

Oui, elles peuvent jouer un rôle dans des maladies inflammatoires de l'intestin.
Maladies inflammatoires de l'intestin Symptômes digestifs

Prévention 5

#1

Peut-on prévenir les maladies liées aux chimiokines CXC ?

Une bonne hygiène de vie et la gestion du stress peuvent aider à prévenir certaines maladies.
Hygiène de vie Gestion du stress
#2

L'alimentation influence-t-elle les chimiokines CXC ?

Oui, une alimentation riche en antioxydants peut réduire l'inflammation et les chimiokines.
Alimentation Antioxydants
#3

L'exercice physique affecte-t-il les niveaux de chimiokines CXC ?

Oui, l'exercice régulier peut moduler les niveaux de chimiokines et améliorer la santé immunitaire.
Exercice physique Santé immunitaire
#4

Le tabagisme influence-t-il les chimiokines CXC ?

Oui, le tabagisme augmente les niveaux de chimiokines et contribue à l'inflammation.
Tabagisme Inflammation
#5

Le stress chronique affecte-t-il les chimiokines CXC ?

Oui, le stress chronique peut augmenter l'expression des chimiokines et aggraver l'inflammation.
Stress chronique Inflammation

Traitements 5

#1

Quels traitements ciblent les chimiokines CXC ?

Des thérapies biologiques et des inhibiteurs de chimiokines sont en développement.
Thérapies biologiques Inhibiteurs
#2

Les corticostéroïdes affectent-ils les chimiokines CXC ?

Oui, les corticostéroïdes peuvent réduire l'expression des chimiokines CXC dans l'inflammation.
Corticostéroïdes Inflammation
#3

Comment les inhibiteurs de chimiokines CXC fonctionnent-ils ?

Ils bloquent les récepteurs des chimiokines, réduisant ainsi l'inflammation et la migration cellulaire.
Inhibiteurs Récepteurs
#4

Les traitements anti-inflammatoires influencent-ils les chimiokines CXC ?

Oui, ils peuvent moduler les niveaux de chimiokines et améliorer les symptômes inflammatoires.
Traitements anti-inflammatoires Symptômes inflammatoires
#5

Y a-t-il des essais cliniques sur les chimiokines CXC ?

Oui, plusieurs essais cliniques évaluent des traitements ciblant les chimiokines CXC.
Essais cliniques Traitements

Complications 5

#1

Quelles complications peuvent survenir avec des niveaux élevés de chimiokines CXC ?

Des complications incluent des maladies auto-immunes, des infections chroniques et des cancers.
Maladies auto-immunes Infections chroniques
#2

Les chimiokines CXC sont-elles impliquées dans le cancer ?

Oui, elles peuvent favoriser la progression tumorale et la métastase dans certains cancers.
Cancer Métastase
#3

Comment les chimiokines CXC affectent-elles la cicatrisation des plaies ?

Une surproduction peut retarder la cicatrisation en exacerbant l'inflammation.
Cicatrisation Inflammation
#4

Les maladies cardiovasculaires sont-elles liées aux chimiokines CXC ?

Oui, des niveaux élevés de chimiokines sont associés à un risque accru de maladies cardiovasculaires.
Maladies cardiovasculaires Risque
#5

Les chimiokines CXC peuvent-elles causer des troubles neurologiques ?

Oui, elles sont impliquées dans des troubles comme la sclérose en plaques et l'Alzheimer.
Sclérose en plaques Alzheimer

Facteurs de risque 5

#1

Quels facteurs de risque augmentent les niveaux de chimiokines CXC ?

L'obésité, le tabagisme et le stress chronique sont des facteurs de risque connus.
Obésité Tabagisme
#2

Les infections peuvent-elles influencer les chimiokines CXC ?

Oui, les infections aiguës et chroniques peuvent augmenter l'expression des chimiokines.
Infections Expression génique
#3

L'exposition à des polluants affecte-t-elle les chimiokines CXC ?

Oui, l'exposition à des polluants environnementaux peut augmenter les niveaux de chimiokines.
Polluants Environnement
#4

Le vieillissement influence-t-il les chimiokines CXC ?

Oui, le vieillissement peut entraîner une augmentation des niveaux de chimiokines et de l'inflammation.
Vieillissement Inflammation
#5

Les maladies métaboliques sont-elles liées aux chimiokines CXC ?

Oui, des maladies comme le diabète peuvent augmenter les niveaux de chimiokines et l'inflammation.
Diabète Maladies métaboliques
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Chimiokines CXC : Questions médicales les plus fréquentes", "headline": "Chimiokines CXC : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Chimiokines CXC : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-09", "dateModified": "2025-04-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Chimiokines CXC" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Chimiokines", "url": "https://questionsmedicales.fr/mesh/D018925", "about": { "@type": "MedicalCondition", "name": "Chimiokines", "code": { "@type": "MedicalCode", "code": "D018925", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Chimiokine CXCL1", "alternateName": "Chemokine CXCL1", "url": "https://questionsmedicales.fr/mesh/D054360", "about": { "@type": "MedicalCondition", "name": "Chimiokine CXCL1", "code": { "@type": "MedicalCode", "code": "D054360", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.050" } } }, { "@type": "MedicalWebPage", "name": "Chimiokine CXCL16", "alternateName": "Chemokine CXCL16", "url": "https://questionsmedicales.fr/mesh/D000075743", "about": { "@type": "MedicalCondition", "name": "Chimiokine CXCL16", "code": { "@type": "MedicalCode", "code": "D000075743", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.075" } } }, { "@type": "MedicalWebPage", "name": "Chimiokine CXCL5", "alternateName": "Chemokine CXCL5", "url": "https://questionsmedicales.fr/mesh/D054365", "about": { "@type": "MedicalCondition", "name": "Chimiokine CXCL5", "code": { "@type": "MedicalCode", "code": "D054365", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.250" } } }, { "@type": "MedicalWebPage", "name": "Chimiokine CXCL6", "alternateName": "Chemokine CXCL6", "url": "https://questionsmedicales.fr/mesh/D054427", "about": { "@type": "MedicalCondition", "name": "Chimiokine CXCL6", "code": { "@type": "MedicalCode", "code": "D054427", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.300" } } }, { "@type": "MedicalWebPage", "name": "Chimiokine CXCL9", "alternateName": "Chemokine CXCL9", "url": "https://questionsmedicales.fr/mesh/D054370", "about": { "@type": "MedicalCondition", "name": "Chimiokine CXCL9", "code": { "@type": "MedicalCode", "code": "D054370", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.450" } } }, { "@type": "MedicalWebPage", "name": "Chimiokine CXCL10", "alternateName": "Chemokine CXCL10", "url": "https://questionsmedicales.fr/mesh/D054357", "about": { "@type": "MedicalCondition", "name": "Chimiokine CXCL10", "code": { "@type": "MedicalCode", "code": "D054357", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.500" } } }, { "@type": "MedicalWebPage", "name": "Chimiokine CXCL11", "alternateName": "Chemokine CXCL11", "url": "https://questionsmedicales.fr/mesh/D054371", "about": { "@type": "MedicalCondition", "name": "Chimiokine CXCL11", "code": { "@type": "MedicalCode", "code": "D054371", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.550" } } }, { "@type": "MedicalWebPage", "name": "Chimiokine CXCL12", "alternateName": "Chemokine CXCL12", "url": "https://questionsmedicales.fr/mesh/D054377", "about": { "@type": "MedicalCondition", "name": "Chimiokine CXCL12", "code": { "@type": "MedicalCode", "code": "D054377", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.600" } } }, { "@type": "MedicalWebPage", "name": "Chimiokine CXCL13", "alternateName": "Chemokine CXCL13", "url": "https://questionsmedicales.fr/mesh/D054382", "about": { "@type": "MedicalCondition", "name": "Chimiokine CXCL13", "code": { "@type": "MedicalCode", "code": "D054382", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.650" } } }, { "@type": "MedicalWebPage", "name": "Facteur-4 plaquettaire", "alternateName": "Platelet Factor 4", "url": "https://questionsmedicales.fr/mesh/D010978", "about": { "@type": "MedicalCondition", "name": "Facteur-4 plaquettaire", "code": { "@type": "MedicalCode", "code": "D010978", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.200.120.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Chimiokines CXC", "alternateName": "Chemokines, CXC", "code": { "@type": "MedicalCode", "code": "D019743", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Amin Ullah", "url": "https://questionsmedicales.fr/author/Amin%20Ullah", "affiliation": { "@type": "Organization", "name": "Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China." } }, { "@type": "Person", "name": "Bairong Shen", "url": "https://questionsmedicales.fr/author/Bairong%20Shen", "affiliation": { "@type": "Organization", "name": "Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China." } }, { "@type": "Person", "name": "Gholamhossein Hassanshahi", "url": "https://questionsmedicales.fr/author/Gholamhossein%20Hassanshahi", "affiliation": { "@type": "Organization", "name": "Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Dept. of Hematology, Faculty of Biomed, Biomedical Sciences, Kerman University of Medical Sciences, Kerman, Iran." } }, { "@type": "Person", "name": "Mojgan Noroozi Karimabad", "url": "https://questionsmedicales.fr/author/Mojgan%20Noroozi%20Karimabad", "affiliation": { "@type": "Organization", "name": "Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Electronic address: mojgan.noroozi@yahoo.com." } }, { "@type": "Person", "name": "Tracy M Handel", "url": "https://questionsmedicales.fr/author/Tracy%20M%20Handel", "affiliation": { "@type": "Organization", "name": "Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Effectiveness of gluteal control training in chronic low back pain patients with functional leg length inequality.", "datePublished": "2024-10-18", "url": "https://questionsmedicales.fr/article/39424858", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-74348-x" } }, { "@type": "ScholarlyArticle", "name": "Asymmetric Flexion Contracture is Associated With Leg Length Inequality in Patients With Knee Osteoarthritis: Data From the Osteoarthritis Initiative.", "datePublished": "2023-05-19", "url": "https://questionsmedicales.fr/article/37209935", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.apmr.2023.04.021" } }, { "@type": "ScholarlyArticle", "name": "Induced leg length inequality affects pelvis orientation during upright standing immediately following a sit-to-stand transfer: a pre-post measurement study.", "datePublished": "2023-03-17", "url": "https://questionsmedicales.fr/article/36932408", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12891-023-06302-3" } }, { "@type": "ScholarlyArticle", "name": "[Options and limits of leg length correction in paediatric orthopaedics].", "datePublished": "2023-08-10", "url": "https://questionsmedicales.fr/article/37561147", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00132-023-04420-3" } }, { "@type": "ScholarlyArticle", "name": "Perioperative management of leg-length discrepancy in total hip arthroplasty: a review.", "datePublished": "2023-01-11", "url": "https://questionsmedicales.fr/article/36629905", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00402-022-04759-w" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Chimiokines", "item": "https://questionsmedicales.fr/mesh/D018925" }, { "@type": "ListItem", "position": 6, "name": "Chimiokines CXC", "item": "https://questionsmedicales.fr/mesh/D019743" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Chimiokines CXC - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Chimiokines CXC", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Chimiokines CXC", "description": "Comment diagnostiquer une dysrégulation des chimiokines CXC ?\nQuels tests sont utilisés pour mesurer les chimiokines CXC ?\nLes chimiokines CXC sont-elles liées à des maladies spécifiques ?\nPeut-on détecter les chimiokines CXC dans les biopsies ?\nLes niveaux de chimiokines CXC varient-ils selon l'âge ?", "url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Leg+Length+Inequality#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Chimiokines CXC", "description": "Quels symptômes sont associés à une surproduction de chimiokines CXC ?\nLes chimiokines CXC peuvent-elles causer des symptômes respiratoires ?\nComment les chimiokines CXC affectent-elles le système nerveux ?\nLes chimiokines CXC sont-elles liées à des symptômes cutanés ?\nPeut-on observer des symptômes digestifs liés aux chimiokines CXC ?", "url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Leg+Length+Inequality#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Chimiokines CXC", "description": "Peut-on prévenir les maladies liées aux chimiokines CXC ?\nL'alimentation influence-t-elle les chimiokines CXC ?\nL'exercice physique affecte-t-il les niveaux de chimiokines CXC ?\nLe tabagisme influence-t-il les chimiokines CXC ?\nLe stress chronique affecte-t-il les chimiokines CXC ?", "url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Leg+Length+Inequality#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Chimiokines CXC", "description": "Quels traitements ciblent les chimiokines CXC ?\nLes corticostéroïdes affectent-ils les chimiokines CXC ?\nComment les inhibiteurs de chimiokines CXC fonctionnent-ils ?\nLes traitements anti-inflammatoires influencent-ils les chimiokines CXC ?\nY a-t-il des essais cliniques sur les chimiokines CXC ?", "url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Leg+Length+Inequality#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Chimiokines CXC", "description": "Quelles complications peuvent survenir avec des niveaux élevés de chimiokines CXC ?\nLes chimiokines CXC sont-elles impliquées dans le cancer ?\nComment les chimiokines CXC affectent-elles la cicatrisation des plaies ?\nLes maladies cardiovasculaires sont-elles liées aux chimiokines CXC ?\nLes chimiokines CXC peuvent-elles causer des troubles neurologiques ?", "url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Leg+Length+Inequality#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Chimiokines CXC", "description": "Quels facteurs de risque augmentent les niveaux de chimiokines CXC ?\nLes infections peuvent-elles influencer les chimiokines CXC ?\nL'exposition à des polluants affecte-t-elle les chimiokines CXC ?\nLe vieillissement influence-t-il les chimiokines CXC ?\nLes maladies métaboliques sont-elles liées aux chimiokines CXC ?", "url": "https://questionsmedicales.fr/mesh/D019743?mesh_terms=Leg+Length+Inequality#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysrégulation des chimiokines CXC ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des analyses de cytokines peuvent aider à évaluer les niveaux de chimiokines." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour mesurer les chimiokines CXC ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les dosages ELISA et les tests multiplex sont couramment utilisés pour mesurer les chimiokines." } }, { "@type": "Question", "name": "Les chimiokines CXC sont-elles liées à des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent associées à des maladies inflammatoires et auto-immunes." } }, { "@type": "Question", "name": "Peut-on détecter les chimiokines CXC dans les biopsies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les chimiokines peuvent être détectées dans les tissus par immunohistochimie." } }, { "@type": "Question", "name": "Les niveaux de chimiokines CXC varient-ils selon l'âge ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux de chimiokines peuvent varier avec l'âge et l'état de santé général." } }, { "@type": "Question", "name": "Quels symptômes sont associés à une surproduction de chimiokines CXC ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent inflammation, douleur, fatigue et troubles immunitaires." } }, { "@type": "Question", "name": "Les chimiokines CXC peuvent-elles causer des symptômes respiratoires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont impliquées dans des maladies respiratoires comme l'asthme et la BPCO." } }, { "@type": "Question", "name": "Comment les chimiokines CXC affectent-elles le système nerveux ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent contribuer à des troubles neurologiques en modulant l'inflammation cérébrale." } }, { "@type": "Question", "name": "Les chimiokines CXC sont-elles liées à des symptômes cutanés ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent être impliquées dans des maladies cutanées inflammatoires comme le psoriasis." } }, { "@type": "Question", "name": "Peut-on observer des symptômes digestifs liés aux chimiokines CXC ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent jouer un rôle dans des maladies inflammatoires de l'intestin." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées aux chimiokines CXC ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hygiène de vie et la gestion du stress peuvent aider à prévenir certaines maladies." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle les chimiokines CXC ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut réduire l'inflammation et les chimiokines." } }, { "@type": "Question", "name": "L'exercice physique affecte-t-il les niveaux de chimiokines CXC ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut moduler les niveaux de chimiokines et améliorer la santé immunitaire." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il les chimiokines CXC ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente les niveaux de chimiokines et contribue à l'inflammation." } }, { "@type": "Question", "name": "Le stress chronique affecte-t-il les chimiokines CXC ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter l'expression des chimiokines et aggraver l'inflammation." } }, { "@type": "Question", "name": "Quels traitements ciblent les chimiokines CXC ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies biologiques et des inhibiteurs de chimiokines sont en développement." } }, { "@type": "Question", "name": "Les corticostéroïdes affectent-ils les chimiokines CXC ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les corticostéroïdes peuvent réduire l'expression des chimiokines CXC dans l'inflammation." } }, { "@type": "Question", "name": "Comment les inhibiteurs de chimiokines CXC fonctionnent-ils ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils bloquent les récepteurs des chimiokines, réduisant ainsi l'inflammation et la migration cellulaire." } }, { "@type": "Question", "name": "Les traitements anti-inflammatoires influencent-ils les chimiokines CXC ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent moduler les niveaux de chimiokines et améliorer les symptômes inflammatoires." } }, { "@type": "Question", "name": "Y a-t-il des essais cliniques sur les chimiokines CXC ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, plusieurs essais cliniques évaluent des traitements ciblant les chimiokines CXC." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des niveaux élevés de chimiokines CXC ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des maladies auto-immunes, des infections chroniques et des cancers." } }, { "@type": "Question", "name": "Les chimiokines CXC sont-elles impliquées dans le cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent favoriser la progression tumorale et la métastase dans certains cancers." } }, { "@type": "Question", "name": "Comment les chimiokines CXC affectent-elles la cicatrisation des plaies ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une surproduction peut retarder la cicatrisation en exacerbant l'inflammation." } }, { "@type": "Question", "name": "Les maladies cardiovasculaires sont-elles liées aux chimiokines CXC ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés de chimiokines sont associés à un risque accru de maladies cardiovasculaires." } }, { "@type": "Question", "name": "Les chimiokines CXC peuvent-elles causer des troubles neurologiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont impliquées dans des troubles comme la sclérose en plaques et l'Alzheimer." } }, { "@type": "Question", "name": "Quels facteurs de risque augmentent les niveaux de chimiokines CXC ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'obésité, le tabagisme et le stress chronique sont des facteurs de risque connus." } }, { "@type": "Question", "name": "Les infections peuvent-elles influencer les chimiokines CXC ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections aiguës et chroniques peuvent augmenter l'expression des chimiokines." } }, { "@type": "Question", "name": "L'exposition à des polluants affecte-t-elle les chimiokines CXC ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des polluants environnementaux peut augmenter les niveaux de chimiokines." } }, { "@type": "Question", "name": "Le vieillissement influence-t-il les chimiokines CXC ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut entraîner une augmentation des niveaux de chimiokines et de l'inflammation." } }, { "@type": "Question", "name": "Les maladies métaboliques sont-elles liées aux chimiokines CXC ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme le diabète peuvent augmenter les niveaux de chimiokines et l'inflammation." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 03/04/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Amin Ullah

4 publications dans cette catégorie

Affiliations :
  • Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.

Bairong Shen

4 publications dans cette catégorie

Affiliations :
  • Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.

Gholamhossein Hassanshahi

3 publications dans cette catégorie

Affiliations :
  • Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Dept. of Hematology, Faculty of Biomed, Biomedical Sciences, Kerman University of Medical Sciences, Kerman, Iran.

Tracy M Handel

3 publications dans cette catégorie

Affiliations :
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.

Jing Zhao

2 publications dans cette catégorie

Affiliations :
  • Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.

Rajeev K Singla

2 publications dans cette catégorie

Affiliations :
  • Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine, Institutes for Systems Genetics, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
  • School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.

Christopher T Schafer

2 publications dans cette catégorie

Affiliations :
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, USA.

Qiuyan Chen

2 publications dans cette catégorie

Affiliations :
  • Departments of Biological Sciences and of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.
  • Present address: Dept. of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA.

John J G Tesmer

2 publications dans cette catégorie

Affiliations :
  • Departments of Biological Sciences and of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.

Qin Zheng

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian, Liaoning Province, China.

Joanna Motyka

2 publications dans cette catégorie

Affiliations :
  • Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, 15-269 Bialystok, Poland.

Aleksandra Kicman

2 publications dans cette catégorie

Affiliations :
  • Department of Aesthetic Medicine, Medical University of Bialystok, 15-267 Bialystok, Poland.

Monika Kulesza

2 publications dans cette catégorie

Affiliations :
  • Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, 15-269 Bialystok, Poland.

Sławomir Ławicki

2 publications dans cette catégorie

Affiliations :
  • Department of Population Medicine and Lifestyle Diseases Prevention, Medical University of Bialystok, 15-269 Bialystok, Poland.

Zi Yin

2 publications dans cette catégorie

Affiliations :
  • General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.

Sheng Chen

2 publications dans cette catégorie

Affiliations :
  • General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.

Nicholas G Kounis

2 publications dans cette catégorie

Affiliations :
  • Division of Cardiology, Department of Internal Medicine, University of Patras Medical School, 26500 Patras, Greece.

Ioanna Koniari

2 publications dans cette catégorie

Affiliations :
  • Department of Cardiology, University Hospital of South Manchester, NHS Foundation Trust, Manchester M23 9LT, UK.

Sources (10000 au total)

Asymmetric Flexion Contracture is Associated With Leg Length Inequality in Patients With Knee Osteoarthritis: Data From the Osteoarthritis Initiative.

To evaluate whether knee flexion contracture (FC) was associated with leg length inequality (LLI) and/or morbidity in knee osteoarthritis (OA).... We accessed 2 databases: (1) the Osteoarthritis Initiative (OAI) cohort, including participants with, or at-risk of OA, and (2) the Ottawa Knee Osteoarthritis cross-sectional database (OKOA), includin... Tertiary care academic rheumatology and orthopedic clinics.... Patients with or at-risk of primary OA. We included 881 OAI and 72 OKOA participants (N=953).... Not applicable.... The primary outcome tested the association between the difference in knee extensions of the OA and contralateral knees (the knee extension difference, or KExD) and LLI. This was evaluated using bivari... OAI participants had less severe knee OA [Kellgren and Lawrence (KL) score 1.9±1.3] vs OKOA (KL score 3.4±0.6). The KExD correlated with LLI for both databases (OAI: R=0.167; P≤.001; OKOA: R=0.339; P=... OA-related loss of knee extension was associated with LLI for those with moderate-severe OA. Because LLI correlates with worse knee OA symptoms, discovering an FC should cue clinicians to evaluate for...

Induced leg length inequality affects pelvis orientation during upright standing immediately following a sit-to-stand transfer: a pre-post measurement study.

Leg length inequality (LLI) greater than 20 mm has been associated with low back pain (LBP) and its correction is clinically recommended. Much less is known about the biomechanical effects that LLI be... Twenty-two adult participants (8 female) aged between 18 and 30 years without LBP were enrolled in the study and completed a series of sit-to-stand trials with no heel-lift (0 mm baseline) and heel-li... Left frontal plane rotation of the pelvis increased (p = 0.001), that is, the left side of the pelvis was lower than the right side of the pelvis, and anterior tilt of the pelvis decreased (p = 0.020)... These findings suggest that correcting leg length inequality below the recommended threshold of 20 mm may influence pelvic orientation. Future work can investigate the effects of the altered orientati...

Relationship between perceived and structural leg length discrepancies of patients with hip osteoarthritis dysplasia.

Only few studies have been conducted on leg length discrepancy (LLD) in patients with hip osteoarthritis (OA). This study aimed to examine the relationship between perceived LLD (pLLD) and structural ... We hypothesized that older adults are less likely to perceive LLD than younger adults.... We recruited 125 patients (102 women and 23 men) with hip OA associated with developmental dysplasia of the hip defined as grade 3 or higher according to the Tönnis classification and excluding contra... The absolute difference between pLLD and sLLD was modestly positively correlated with age (R=0.206; p<0.05) indicating older patients were less prone to perceive LLD. A strong positive correlation was... Older patients had less pLLD. Preoperative pLLD was strongly correlated with sLLD but not with patient satisfaction. These results may be useful for conservative treatment of OA, preoperative planning... IV; case control study....

Magnitude of Change in Leg Length and Clinical Impact Following Medial Unicompartmental Knee Arthroplasty.

Change in leg length and leg-length discrepancy (LLD) are common concerns among patients undergoing medial unicompartmental knee arthroplasty (UKA). This study aimed to quantify the magnitude of leg-l... Leg length and mechanical hip-knee-ankle angle (mHKA) were retrospectively measured in 332 patients following unilateral robotic-arm assisted medial UKA for medial compartment osteoarthritis, using ca... Following medial UKA, median leg-length change was 2.0 mm (interquartile range, -1.0 to 5.0 mm; P < .001) with a mean correction in mHKA of 4.4° ± 2.7 (P < .001). A total of 158 patients (48%) had a l... Following medial UKA, the majority of patients had a moderate increase in leg length, the magnitude of which was positively correlated to the correction in mechanical alignment. Postoperative substant...

Clinically Detected Leg Length Discrepancy in Patients With Idiopathic Clubfoot Deformity: Prevalence and Outcomes.

This study evaluates the prevalence and outcomes of patients with idiopathic clubfoot and clinically detected limb length discrepancy (LLD).... This is a retrospective cohort study of idiopathic clubfoot patients in a Research Ethics Board-approved clubfoot registry. Patients with LLD ≥0.5 cm (LLD+) were compared with those with no or <0.5 cm... Of the 300 patients included, 27 (9.0%) had an LLD, of whom 23 patients had a unilateral clubfoot deformity. The prevalence of LLD was 15.3% and 2.67% in unilateral and bilateral clubfoot patients, re... LLD was present in 9% of idiopathic clubfoot patients, and most were <2 cm. There is a significantly higher risk of relapse in patients with unilateral clubfoot and LLD. The risk of surgery overall wa... Level III....

Measurement Techniques for Leg Length Discrepancy in Total Hip Arthroplasty: A Systematic Review of Reliability and Validity.

Total hip arthroplasty (THA) carries a substantial litigative burden. THA may introduce leg length discrepancy (LLD), necessitating a valid and reliable technique for LLD measurement. This study inves... Embase and MEDLINE databases were searched following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for articles assessing either the validity or reliability of LLD meas... Forty-two articles with 2059 participants were included. Thirty-three investigated reliability and 25 validity. Reliability displayed high heterogeneity. Poor to excellent intra-rater reliability was ... The reported intra- and inter-rater reliability for most measurement techniques vary widely. The tape measure method is a valid clinical measurement of LLD. Imaging techniques have been appropriately ...

Leg length discrepancies (LLD): An etiology to be considered in its proper measure. A critical and historical review.

Studies of leg-length discrepancies (LLD) have been the subject of debate for almost 200 years. A large number of studies have emerged, most frequently using assessment criteria based on painful sympt... While many authors argue for a threshold of 10-20 mm to establish a link between pain and LLD, most publications based on radiography show lesion stigmata on lumbar, hip and knee joints as early as 6 ... Some studies argue forcefully that leg-length correction below 20 mm is of no benefit. The authors of the present article, on the other hand, evoke the notion of lesion risks in the absence of correct... The authors argue for the need to define in the future a lesion significance score that would not be correlated to painful symptomatology, but rather to the presence of co-morbidities such as age, ana...